Feature

Sen. Schumer backs federal decriminalization of marijuana


 

U.S. Sen. Chuck Schumer, the Senate majority leader, is cosponsoring legislation that would decriminalize marijuana at the federal level.

Marijuana leaves VladK213/Getty Images

The Cannabis Administration & Opportunity Act would allow the federal government to regulate and tax marijuana sales for the first time and would stop the federal prosecution of people for possessing and selling the drug, The New York Times reported. States could still make their own marijuana laws, however.

The bill calls for using money raised by taxing marijuana to help poor people and communities of color that have been unduly affected by marijuana laws.

Arrests and convictions for nonviolent marijuana offenses would be automatically expunged, The New York Times reported.

“The War on Drugs has been a war on people – particularly people of color,” a draft of the bill said, adding that the bill “aims to end the decades of harm inflicted on communities of color by removing cannabis from the federal list of controlled substances and empowering states to implement their own cannabis laws.”

But passage of the bill is highly uncertain because of strong Republican opposition in the Senate, where Democrats hold a narrow majority, according to The New York Times.

President Biden has not said he supports such legislation.

Sen. Schumer signaled his intentions when he spoke on April 20, the unofficial holiday for marijuana smokers.

“Hopefully, the next time this unofficial holiday of 4/20 rolls around, our country will have made progress in addressing the massive overcriminalization of marijuana in a meaningful and comprehensive way,” he said at the time, the newspaper reported.

Cosponsors were U.S. Sen. Cory Booker of New Jersey and U.S. Sen. Ron Wyden of Oregon, chairman of the Senate Finance Committee.

A version of this article first appeared on WebMD.com.

Recommended Reading

Women increasingly turn to CBD, with or without doc’s blessing
MDedge Psychiatry
Cannabinoids may pose death risk for older patients with COPD
MDedge Psychiatry
FDA warning letters target OTC cannabidiol product claims for pain relief
MDedge Psychiatry
Cannabinoid-based medications for pain
MDedge Psychiatry
Doctors more likely to prescribe opioids to COVID ‘long-haulers,’ raising addiction fears
MDedge Psychiatry
The cloudy role of cannabis as a neuropsychiatric treatment
MDedge Psychiatry
FDA OKs higher-dose naloxone nasal spray for opioid overdose
MDedge Psychiatry
Transcranial brain stimulation can modulate placebo and nocebo experiences
MDedge Psychiatry
Physician convicted in buprenorphine scheme faces up to 20 years in prison
MDedge Psychiatry
Chronic headache pain in veterans linked to suicide attempts
MDedge Psychiatry